Immune Repertoire Sequencing Market To Reach $894.2 Million By 2033

Immune Repertoire Sequencing Market Growth & Trends

The global immune repertoire sequencing market size is projected to reach USD 894.2 million by 2033, growing at a CAGR of 11.89% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is experiencing robust growth, driven by the increasing demand for high-resolution immune profiling to support next-generation immunotherapies, vaccine development, and precision medicine. As immune-driven diseases become more complex, researchers require sequencing solutions that can reliably capture clonal diversity, track immune responses, and characterize T- and B-cell dynamics with greater accuracy.

Data-intensive, high-throughput sequencing platforms that can provide deeper insights into adaptive immunity are clearly replacing traditional, low-throughput immunoassays in the market. To improve repertoire characterization, reduce analytical variability, and enhance clonotype detection, developers are increasingly utilizing AI-enabled analytics, advanced NGS technologies, and complex bioinformatics pipelines.

The development of personalized vaccines, precision immunotherapies, and cell and gene therapies has made immune repertoire sequencing an essential tool for clinical decision-making and translational research. The market is positioned as a crucial part of the global immunology and precision health innovation ecosystem, resulting from the technology's acceleration of biomarker discovery, therapy monitoring, and patient stratification.

 Request a free sample copy or view report summary: Immune Repertoire Sequencing Market Report

Immune Repertoire Sequencing Market Report Highlights

• By product & service, the assay kits & reagents segment accounted for the largest market share of 49.95% in 2024. This dominance is fueled by the broad use of multiplex PCR reagents, targeted enrichment solutions, and NGS-ready library preparation kits. The segment's leadership was further reinforced by ongoing advancements in sequencing chemistry, workflow automation, and reagents that enhance accuracy and precision.

• By type, bulk immune repertoire sequencing held the leading share of 64.66% in 2024. Its cost-effectiveness, scalable workflow, and suitability for large-cohort immunology studies have accelerated adoption across research and translational applications. Advances in high-throughput sequencing platforms and optimized multiplexing strategies have reinforced its market prominence.

• By application, oncology & cancer immunotherapy dominated the market in 2024 with a share of 37.86%. The increasing utilization of TCR/BCR profiling for tumor-infiltrating lymphocyte (TIL) analysis, immune checkpoint response assessment, and biomarker discovery has fueled the growth of this segment. The expanding pipeline of immunotherapies and personalized cancer vaccines continues to elevate demand.

• By end-use, academic & research institutes captured the largest share of 46.77%, in 2024. Significant uptake has been fueled by their growing emphasis on immunogenomics, translational cancer research, studies on infectious disease immunity, and vaccine response monitoring. Their dominant position is further reinforced by expanding access to bioinformatics tools and high-throughput sequencing infrastructure.

Immune Repertoire Sequencing Market Segmentation

Grand View Research has segmented the global immune repertoire sequencing market based on product & service, type, application, end-use, and region:

Immune Repertoire Sequencing Product & Service Outlook (Revenue, USD Million, 2021 - 2033)

• Instruments

• Assay Kits & Reagents      

  • TCR kits

  • BCR kits

  • Others

• Services

Immune Repertoire Sequencing Type Outlook (Revenue, USD Million, 2021 - 2033)

• Bulk immune-repertoire sequencing

• Single-cell immune-repertoire sequencing

Immune Repertoire Sequencing Application Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology & Cancer Immunotherapy

• Autoimmune & Inflammatory Diseases

• Infectious Diseases & Vaccine Development

• Transplantation & Immune Tolerance

• Others

Immune Repertoire Sequencing End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Academic & Research Institutes

• Pharmaceutical & Biotechnology Companies

• Others

Immune Repertoire Sequencing Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Immune Repertoire Sequencing Market

• QIAGEN

• New England Biolabs

• Takara Bio

• Illumina, Inc.

• iRepertoire

• BGI

• Danaher

• Creative Biolabs

• Nucleus Biotech

• Celemics, Inc.